Information  X 
Enter a valid email address

Company Name matching 'Minerva Neurosciences, Inc'

Date
Time Source
Company
Announcement
24 Jun 2019 12:30 pm GNW     Minerva Neurosciences, Inc Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia
23 Jun 2019 10:30 pm GNW     Minerva Neurosciences, Inc Minerva Neurosciences to Host Live Conference Call and Webcast With Key Opinion Leaders to Discuss Successful Insomnia Trial With Seltorexant
12 Jun 2019 1:30 pm GNW     Minerva Neurosciences, Inc Minerva Neurosciences to Present at JMP Securities Life Sciences Conference
29 May 2019 1:30 pm GNW     Minerva Neurosciences, Inc Minerva Neurosciences to Present at Jefferies 2019 Global Healthcare Conference on June 4, 2019
13 May 2019 1:15 pm GNW     Minerva Neurosciences, Inc Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs
06 May 2019 12:30 pm GNW     Minerva Neurosciences, Inc Minerva Neurosciences Reports First Quarter 2019 Financial Results and Business Updates
18 Mar 2019 12:30 pm GNW     Minerva Neurosciences, Inc Minerva Neurosciences to Host Webcast Event on Schizophrenia
12 Mar 2019 11:30 am GNW     Minerva Neurosciences, Inc Minerva Neurosciences Reports Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates
05 Mar 2019 1:00 pm GNW     Minerva Neurosciences, Inc Minerva Neurosciences to Report Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2019
28 Nov 2018 1:00 pm GNW     Minerva Neurosciences, Inc Minerva Neurosciences Announces New Patent Application for MIN-117 Related to Broad Effect on Pain
21 Nov 2018 1:30 pm GNW     Minerva Neurosciences, Inc Minerva Neurosciences to Present at Evercore ISI HealthCONx Conference on November 28, 2018
19 Nov 2018 1:00 pm GNW     Minerva Neurosciences, Inc Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers
15 Nov 2018 1:30 pm GNW     Minerva Neurosciences, Inc Minerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 2018
05 Nov 2018 12:30 pm GNW     Minerva Neurosciences, Inc Minerva Neurosciences Reports Third Quarter 2018 Financial Results and Business Updates
29 Oct 2018 12:30 pm GNW     Minerva Neurosciences, Inc Minerva Neurosciences to Report Third Quarter 2018 Financial Results and Business Updates on November 5, 2018
22 Aug 2018 1:30 pm GNW     Minerva Neurosciences, Inc Minerva Neurosciences Announces Findings Showing Effect of Roluperidone on Brain-Derived Neurotrophic Factor (BDNF)
02 Aug 2018 12:30 pm GNW     Minerva Neurosciences, Inc Minerva Neurosciences Reports Second Quarter 2018 Financial Results and Business Updates
26 Jul 2018 1:30 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences to Report Second Quarter 2018 Financial Results and Business Updates on August 2, 2018
25 Jul 2018 1:00 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences Names Devin Smith Senior Vice President, General Counsel
17 Jul 2018 9:05 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors
30 May 2018 1:30 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences to Present at Jefferies 2018 Global Healthcare Conference on June 6, 2018
17 May 2018 1:00 pm GNW     Minerva Neurosciences, Inc. Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symp...
03 May 2018 12:30 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates
09 Apr 2018 1:30 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder
15 Mar 2018 12:30 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday, March 22
12 Mar 2018 11:30 am GNW     Minerva Neurosciences, Inc. Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates
05 Mar 2018 1:30 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2018
05 Feb 2018 1:30 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director
21 Dec 2017 1:00 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With...
19 Dec 2017 1:00 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia
11 Dec 2017 9:40 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences Names Richard Russell President
  1:15 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors
06 Dec 2017 1:30 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia Disorder
08 Nov 2017 2:00 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences to Present at Jefferies 2017 London Healthcare Conference on November 15, 2017
06 Nov 2017 12:30 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences Reports Third Quarter 2017 Financial Results and Business Updates
31 Oct 2017 12:00 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences Names Dr. Justine Lalonde as Senior Vice President, Product Strategy
30 Oct 2017 12:30 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences to Report Third Quarter 2017 Financial Results and Business Updates on November 6, 2017
11 Sep 2017 1:30 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences Names Dr. Jay Saoud as Senior Vice President, Head of Research and Development
05 Sep 2017 1:00 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder
25 Aug 2017 1:30 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences Announces European Commission Approval of Amendment of MIN-202 Agreement With Janssen
03 Aug 2017 12:30 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences Reports Second Quarter 2017 Financial Results and Business Updates
31 Jul 2017 1:30 pm GNW     Minerva Neurosciences, Inc. American Journal of Psychiatry Publishes Minerva Neurosciences' MIN-101 Phase 2b Trial Results for Treatment of Negative Symptoms in Schizophrenia
27 Jul 2017 1:30 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 2017
24 Jul 2017 1:30 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences Announces Departure of Directors
05 Jul 2017 9:05 pm GNW     Minerva Neurosciences, Inc. Minerva Neurosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t